Korean J Fam Pract. 2017; 7(4): 513-519  https://doi.org/10.21215/kjfp.2017.7.4.513
Primary Prevention Effectiveness of Aspirin in Korean Elderly: Effect of Aspirin on Mortality in Elderly Patients with Hypertension, Diabetes Mellitus or Dyslipidemia
Seung-Hyun Choi1, Jong Lull Yoon1,*, Soo-Jin Cheong1, Ae-Young Lee1, Hak-Sun Kim1, Yu-Jin Jung1, Mee-Young Kim1, Jung-Jin Cho1, Young-Soo Ju2
1Department of Family Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong; 2Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
Jong Lull Yoon
Tel: +82-31-8086-2390, Fax: +82-31-8086-2709
E-mail: lull@hallym.or.kr
Received: July 11, 2016; Revised: August 30, 2016; Accepted: September 17, 2016; Published online: August 20, 2017.
© Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Aspirin is well known for its central role as an antiplatelet agent in preventing cardio-cerebro-vascular diseases. Its secondary prevention effect is well established; however, its use in primary prevention of cardiovascular or cebrovascular disease in healthy people is still controversial. The aim of this study was to estimate the effect of aspirin in elderly patients with hypertension, diabetes mellitus, or dyslipidemia.
Methods: A retrospective study was conducted using data from the National Health Insurance Service Senior Cohort. Patients with past medical history of cardio-cerebro-vascular disease or cancers and medication history of antiplatelet agents such as aspirin, warfarin, and clopidogrel were excluded from the study, while patients with one or more of the chronic diseases hypertension, diabetes mellitus, and dyslipidemia were included (n=145,769). We analyzed mortality from 2003 to 2007 in the no aspirin group and in groups taking aspirin for 1 year, 2 to 3 years, and 3 to 5 years.
Results: Total mortality was 9.8% in the control group and 16.0% (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.6–2.5), 17.7% (HR, 1.6; 95% CI, 1.5–1.8), and 18.4% (HR, 2.0; 95% CI, 1.3–3.0) in the groups taking aspirin for 1 year, 2 to 3 years, and 3 to 5 years, respectively. Mortality caused by cardiovascular or cerebrovascular disease was higher in aspirin groups than in the control group.
Conclusion: We found that the use of aspirin for primary prevention increased total mortality and mortality due to cardiovascular and cerebrovascular disease in elderly Korean patients over 60 years of age with one or more chronic diseases.
Keywords: Aspirin; Mortality; Primary Prevention; Cardiovascular Disease; Cerebrovascular Disease; Aged
  1. World Health Organization. The top 10 causes of death [Internet]. Geneva:World Health Organization; 2011 [cited 2013 Dec 27].
  2. World Health Organization. Cancer fact sheet [Internet]. Geneva: World Health Organization; 2013 [cited 2013 Dec 27].
  3. Park HS. Statistical analytic data of mortality and causes of deaths, 2012. Daejeon: Korea National Statistical Office; 2013.
  4. Organisation for Economic Co-operation and Development. Health at a glance 2015: OECD Indicators [Internet]. Paris: OECD Publishing; 2015 [cited 2015 Dec 8].
  5. Statistics Korea. Annual report on the vital statistics in Korea [Internet]. Daejeon: Statistics Korea; 2015 [cited 2015 Dec 8].
    Available from: http://kostat.go.kr/
  6. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.
  7. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81-106.
    Pubmed KoreaMed CrossRef
  8. Paek YJ, Yoon JL. Aspirin in the prevention of cardiovascular disease and cancer. J Korean Med Assoc 2014; 57: 348-56.
  9. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-16.
    Pubmed CrossRef
  10. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
  11. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J 2013; 77: 3023-8.
    Pubmed CrossRef
  12. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134-41.
    Pubmed CrossRef
  13. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
    Pubmed CrossRef
  14. Kim YJ, Kwak C. Prevalence and associated risk factors for cardiovascular disease: findings from the 2005, 2007 Korea National Health and Nutrition Examination Survey. Korean J Health Promot 2011; 11: 169-76.
  15. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
  16. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352:1801-7.
  17. Ueda K, Hasuo Y, Kiyohara Y, Wada J, Kawano H, Kato I, et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 1988; 19: 48-52.
    Pubmed CrossRef
  18. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10.
    Pubmed CrossRef
  19. Park HS, Kang MJ, Huh JT. Recent epidemiological trends of stroke. J Korean Neurosurg Soc 2008; 43: 16-20.
    Pubmed KoreaMed CrossRef
  20. Epidemiology of cerebrovascular disease in Korea--a Collaborative Study, 1989-1990. Korean Neurological Association. J Korean Med Sci 1993; 8:281-9.
    Pubmed KoreaMed CrossRef
  21. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
    Pubmed KoreaMed CrossRef

This Article